<DOC>
	<DOCNO>NCT02939807</DOCNO>
	<brief_summary>This Phase II efficacy study single agent ABC294640 . Patients advance hepatocellular carcinoma ( HCC ) experience tumor progression 1st line single agent sorafenib receive ABC294640 500 mg po bid continuously . Patients continue therapy development progressive disease per modify RECIST , intolerable toxicity , withdrawal patient consent event outline patient discontinuation .</brief_summary>
	<brief_title>A Phase II Study ABC294640 Second-Line Monotherapy Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>1 . Patient must advance hepatocellular carcinoma ; fibrolamellar HCC allow . Hepatocellular carcinoma confirm least one following : 1 . Tissue diagnosis . 2 . The presence one liver lesion measure ≥ 2 cm long diameter , show characteristic arterial enhancement venous washout use arterialphase contrast enhance imaging , clinical history cirrhosis 2 . Voluntary sign dated institutional review board ( IRB ) approve informed consent form accordance regulatory institutional guideline . 3 . Documented progression intolerance sorafenib demonstrate : 1 . Radiographic ( mRECIST , see APPENDIX F ) symptomatic progression on/after sorafenib 2 . Intolerance sorafenib consist CTCAE grade 2 great drugrelated AE persist spite comprehensive supportive therapy accord institutional standard AND persist recurred sorafenib treatment interruption least 7 day dose reduction one dose level ( 400 mg daily ) . 4 . Patient must least one measurable untreated lesion per modify RECIST criterion . Measurable disease may include extrahepatic lesion . Abdominal image employ `` liver protocol '' image capture technique . The following consider measurable lesion : bone lesion , ascites , pleural effusion . Prior RFA , PEI , TACE nontarget lesion allow . 5 . Time interval last local therapy ( radiofrequency ablation , percutaneous ethanol injection , radiotherapy , transarterial chemoembolization ) 4 week prior registration . 6 . Willingness undergo core biopsy primary hepatic tumor , metastatic site prior baseline Cycle 2 Day 1 . 7 . Life expectancy least 12 week . 8 . 18 year age old . 9 . ECOG performance status 02 . 10 . ChildPugh Class A OR B score 7 . 11 . Acceptable liver function : 1 . Bilirubin ≤ 3 time upper limit normal ( CTCAE Grade 2 baseline ) 2 . AST ( SGOT ) &amp; ALT ( SGPT ) ≤ 3 x ULN ( CTCAE Grade 1 baseline ) 12 . Acceptable kidney function : a. Serum creatinine ≤ 1.5 X ULN ( CTCAE Grade 1 baseline ) 13 . Acceptable hematologic status : 1 . Absolute neutrophil count ≥ 1000 cells/mm3 , 2 . Platelet count ≥ 75,000 ( plt/mm3 ) ( CTCAE Grade 1 baseline ) 3 . Hemoglobin ≥ 9.0 g/dL . 14 . Acceptable blood sugar control : a. Fasting glucose ≤ 160 mg/dL ( CTCAE Grade 1 baseline ) 15 . Urinalysis : No clinically significant abnormality . 16. International normalize ratio ( INR ) ≤ 1.7 17 . As determined treat investigator , patient must wellcontrolled blood pressure , define systolic blood pressure &lt; 150mmHg and/or diastolic blood pressure &lt; 100 mmHg majority measurement . 18 . A negative pregnancy test ( female child bear potential ) . 19 . Willingness use effective contraceptive method study . If female ( female partner male subject ) , either childbearing potential ( define postmenopausal ≥ 1 year surgically sterile ) practice two form contraception . Sexually active male participant must agree use physical barrier method ( male latex rubber condom without spermicide ) . 1 . New York Heart Association Class III IV , cardiac disease , myocardial infarction within past 6 month , unstable arrhythmia , evidence ischemia ECG . 2 . Underlying psychiatric disorder require pharmacological intervention Hospital Anxiety Depression Scale ( HADS ) score 8 . 3 . Neurological disorder ( Parkinson 's disease , dementia , Multiple sclerosis ) 4 . Active , uncontrolled bacterial , viral fungal infection , require systemic therapy . 5 . Pregnant nursing woman . NOTE : Women childbearing potential men must agree use adequate contraception abstinence prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 6 . Treatment radiation therapy , surgery , investigational therapy within 28 day prior registration 7 . More one line prior systemic therapy HCC . 8 . Unwillingness inability comply procedure require protocol . 9 . Known infection HIV . 10 . Hepatitis C protease therapy . 11 . Serious nonmalignant disease could compromise protocol objective opinion Investigator . 12 . Patients receive drug sensitive substrate CYP450 1A2 , 3A4 , 2C9 , 2C19 2D6 , strong inhibitor inducer major CYP450 isozymes stop least 7 day 5 halflives ( whichever longer ) start treatment ABC294640 either replace another appropriate medication give duration clinical study . 13 . A history CTC Grade 3 bleed esophageal gastric varix within past 2 month . Prior variceal bleed permit patient undergone band sclerotherapy evidence bleed 2 month . Patients risk varix ( base following : know history esophageal gastric varix ; evidence hepatic cirrhosis and/or portal hypertension include biopsyproven cirrhosis , hypersplenism , radiographic finding varix ) screen ( use either esophagogastroduodenoscopy [ EGD ] capsule endoscopy ) esophageal varix , unless screen perform past two year study entry patient receive medical treatment prophylaxis variceal bleeding , nonselective beta blockade . If varix identify require intervention ( band ) , patient eligible varix adequately treat . Patients present gastric varix eligible study . 14 . Patients currently take Coumadin Coumadin derivative . 15 . Patients currently participate clinical trial investigational product . 16 . History organ transplantation . 17 . Other primary malignancy within past 5 year except carcinoma situ cervix urinary bladder nonmelanoma skin cancer . 18 . Mental incapacitation psychiatric illness would preclude study participation . 19 . Prisoners patient compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Yeliva™</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>ABC294640</keyword>
	<keyword>hepatic neoplasm</keyword>
	<keyword>liver neoplasm</keyword>
	<keyword>hepatic cancer</keyword>
</DOC>